Skip to main content

Table 1 Summary of results from studies reporting anti-HCV prevalence in the general population

From: Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update

Author, year

Country

Recruiting period

Population as reported

Age, mean (SD)

Sample size

Anti-HCV prevalence (%) (95% CI)

Risk of selection bias

Viejo, 2018 [19]

Spain

February–April 2017

The general adult population living in the health area of Callosa D’En Sarrià

47.5 (−)

2637

1.14 (0.73–1.55)

High risk

Lavin, 2017 [20]

Spain

2015–2016

Spanish adult population

–

6839

1.11 (−)

Low risk

Quesada, 2015 [21]

Spain

1994–2005

Women from the general population in different geographical areas worldwide

40.0(15.6)

314

0.60 (0.20–2.50)

High risk

Andriulli, 2018 [22]

Italy

2015

The general population

–

4907

2.30 (−)

Low risk

Morisco, 2017 [23]

Italy

May 14

A random 1:3 systematic sample of the adult general population of Naples

49.9(5.00)

1315

3.00 (2.10–4.00)

Low risk

Walewska-Zielecka, 2017 [24]

Poland

2004–2014

Patients who had been tested for anti-HCV at least once in the period from 2004 to 2014

34.4(8.6)

61805

1.50 (−)

High risk

Clifford, 2017 [25]

Poland

2004–2009

The general female population

37.0(−)

909

0.80 (0.30–1.60)

High risk

Garvey, 2017 [26]

Ireland

April–June 2014 and November 2015–February 2016

The adult population in Ireland with probability proportional to the general population age-sex distribution

–

3759

0.98 (−)

Low risk

Chlibek, 2017 [27]

Czech Republic

February 2015–September 2015

The adult general population

47.1(17.1)

3000

1.67 (1.27–2.19)

High risk

Carvalhana, 2016 [28]

Portugal

April 2012–December 2014

Adults from primary care settings in mainland Portugal

50.2(18.3)

1627

0.54 (0.20–0.90)

Low risk

Plompen, 2015 [29]

Netherland

−

The general Dutch elderly population

69.5(9.0)

6036

0.56 (−)

High risk